Compare WULF & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | NVAX |
|---|---|---|
| Founded | 1952 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 1.1B |
| IPO Year | 1995 | 1995 |
| Metric | WULF | NVAX |
|---|---|---|
| Price | $11.39 | $6.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 8 |
| Target Price | ★ $17.04 | $9.75 |
| AVG Volume (30 Days) | ★ 28.1M | 3.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | $167,604,000.00 | ★ $1,064,651,000.00 |
| Revenue This Year | $30.84 | $58.91 |
| Revenue Next Year | $123.19 | N/A |
| P/E Ratio | ★ N/A | $3.29 |
| Revenue Growth | ★ 30.58 | 20.27 |
| 52 Week Low | $2.06 | $5.01 |
| 52 Week High | $17.05 | $11.55 |
| Indicator | WULF | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 45.92 |
| Support Level | $11.32 | $6.36 |
| Resistance Level | $13.64 | $7.00 |
| Average True Range (ATR) | 1.08 | 0.20 |
| MACD | -0.27 | 0.06 |
| Stochastic Oscillator | 2.71 | 60.16 |
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.